Abstract

Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are two distinct autoimmune diseases that manifest with chronic synovial inflammation. Here, we show that CD4+ T cells from patients with RA and PsA have increased expression of the pore-forming calcium channel component ORAI3, thereby increasing the activity of the arachidonic acid-regulated calcium-selective (ARC) channel and making T cells sensitive to arachidonic acid. A similar increase does not occur in T cells from patients with systemic lupus erythematosus. Increased ORAI3 transcription in RA and PsA T cells is caused by reduced IKAROS expression, a transcriptional repressor of the ORAI3 promoter. Stimulation of the ARC channel with arachidonic acid induces not only a calcium influx, but also the phosphorylation of components of the T cell receptor signaling cascade. In a human synovium chimeric mouse model, silencing ORAI3 expression in adoptively transferred T cells from patients with RA attenuates tissue inflammation, while adoptive transfer of T cells from healthy individuals with reduced expression of IKAROS induces synovitis. We propose that increased ARC activity due to reduced IKAROS expression makes T cells more responsive and contributes to chronic inflammation in RA and PsA.

ORAI3 is part of pore forming calcium channels involved in T cell activation. Here the authors show that there is increased expression of ORAI3 in T cells from patients with rheumatoid arthritis and that the transcription factor IKAROS negatively regulates the ORAI3 promoter, indicating a regulatory loop that can control auto-reactivity of T cells in these patients.

Details

Title
Arachidonic acid-regulated calcium signaling in T cells from patients with rheumatoid arthritis promotes synovial inflammation
Author
Ye Zhongde 1 ; Shen, Yi 2 ; Jin, Ke 2 ; Qiu Jingtao 2   VIAFID ORCID Logo  ; Hu, Bin 3   VIAFID ORCID Logo  ; Jadhav, Rohit R 3   VIAFID ORCID Logo  ; Sheth Khushboo 4   VIAFID ORCID Logo  ; Weyand, Cornelia M 3   VIAFID ORCID Logo  ; Goronzy, Jörg J 3   VIAFID ORCID Logo 

 Palo Alto Veterans Administration Healthcare System, Department of Medicine, Palo Alto, USA; Stanford University, Department of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 Stanford University, Department of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 Palo Alto Veterans Administration Healthcare System, Department of Medicine, Palo Alto, USA (GRID:grid.168010.e); Stanford University, Department of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 Palo Alto Veterans Administration Healthcare System, Department of Medicine, Palo Alto, USA (GRID:grid.168010.e) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2488038632
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.